Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

John Corboy to Multiple Sclerosis

This is a "connection" page, showing publications John Corboy has written about Multiple Sclerosis.

 
Connection Strength
  
 
 
8.393
  
  1. Wolf AB, Alvarez E, Corboy JR. Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis-Variations in Real-World Experience. JAMA Neurol. 2024 Jan 01; 81(1):87.
    View in: PubMed
    Score: 0.651
  2. Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, Engebretson E, Gustafson T, Miller AE. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol. 2023 07; 22(7):568-577.
    View in: PubMed
    Score: 0.628
  3. Shah AA, Wolf AB, Declusin A, Coleman K, Kammeyer R, Khan B, Corboy JR. Challenging Cases in Neuroimmunology. Semin Neurol. 2022 12; 42(6):695-707.
    View in: PubMed
    Score: 0.610
  4. Strijbis EMM, Kerbrat A, Corboy JR. Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go? JAMA Neurol. 2021 07 01; 78(7):787-788.
    View in: PubMed
    Score: 0.547
  5. Mowry EM, Corboy JR. Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosis. Lancet Neurol. 2019 11; 18(11):983-985.
    View in: PubMed
    Score: 0.482
  6. Gross RH, Corboy JR. Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies. Continuum (Minneap Minn). 2019 Jun; 25(3):715-735.
    View in: PubMed
    Score: 0.473
  7. Corboy JR, Weinshenker BG, Wingerchuk DM. Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS. Neurology. 2018 06 12; 90(24):1106-1112.
    View in: PubMed
    Score: 0.439
  8. Solomon AJ, Corboy JR. The tension between early diagnosis and misdiagnosis of multiple sclerosis. Nat Rev Neurol. 2017 Sep; 13(9):567-572.
    View in: PubMed
    Score: 0.418
  9. Kister I, Corboy J. Author response: Reducing costs while enhancing quality of care in MS. Neurology. 2017 03 21; 88(12):1212.
    View in: PubMed
    Score: 0.407
  10. Kister I, Corboy JR. Reducing costs while enhancing quality of care in MS. Neurology. 2016 Oct 11; 87(15):1617-1622.
    View in: PubMed
    Score: 0.392
  11. Miravalle A, Corboy JR. Therapeutic options in multiple sclerosis: five new things. Neurology. 2010 Nov 02; 75(18 Suppl 1):S22-7.
    View in: PubMed
    Score: 0.261
  12. Brousseau KM, Arciniegas DB, Carmosino MJ, Corboy JR. The differential diagnosis of Axis I psychopathology presenting to a university-based multiple sclerosis clinic. Mult Scler. 2007 Jul; 13(6):749-53.
    View in: PubMed
    Score: 0.203
  13. Carmosino MJ, Brousseau KM, Arciniegas DB, Corboy JR. Initial evaluations for multiple sclerosis in a university multiple sclerosis center: outcomes and role of magnetic resonance imaging in referral. Arch Neurol. 2005 Apr; 62(4):585-90.
    View in: PubMed
    Score: 0.177
  14. Solomon AJ, Arrambide G, Brownlee WJ, Flanagan EP, Amato MP, Amezcua L, Banwell BL, Barkhof F, Corboy JR, Correale J, Fujihara K, Graves J, Harnegie MP, Hemmer B, Lechner-Scott J, Marrie RA, Newsome SD, Rocca MA, Royal W, Waubant EL, Yamout B, Cohen JA. Differential diagnosis of suspected multiple sclerosis: an updated consensus approach. Lancet Neurol. 2023 08; 22(8):750-768.
    View in: PubMed
    Score: 0.158
  15. Shafit-Zagardo B, Sidoli S, Goldman JE, DuBois JC, Corboy JR, Strittmatter SM, Guzik H, Edema U, Arackal AG, Botbol YM, Merheb E, Nagra RM, Graff S. TMEM106B Puncta Is Increased in Multiple Sclerosis Plaques, and Reduced Protein in Mice Results in Delayed Lipid Clearance Following CNS Injury. Cells. 2023 06 27; 12(13).
    View in: PubMed
    Score: 0.157
  16. Barrera B, Simpson H, Engebretson E, Sillau S, Valdez B, Parra-Gonz?lez J, Winger RC, Epperson LA, Banks A, Pierce K, Spotts M, O'Gean K, Alvarez E, Gross R, Piquet AL, Schreiner T, Corboy JR, Pei J, Vollmer TL, Nair KV. Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis. Ann Clin Transl Neurol. 2023 04; 10(4):579-588.
    View in: PubMed
    Score: 0.153
  17. Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord. 2021 Oct; 55:103170.
    View in: PubMed
    Score: 0.137
  18. Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020 09; 7(9):1477-1487.
    View in: PubMed
    Score: 0.128
  19. Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019 Nov; 36:101402.
    View in: PubMed
    Score: 0.121
  20. Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 05; 25(5):845-854.
    View in: PubMed
    Score: 0.116
  21. Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2019 02; 6(2):252-262.
    View in: PubMed
    Score: 0.115
  22. Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E. The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis. J Neurol Sci. 2018 07 15; 390:89-93.
    View in: PubMed
    Score: 0.109
  23. Hassani A, Corboy JR, Al-Salam S, Khan G. Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLoS One. 2018; 13(2):e0192109.
    View in: PubMed
    Score: 0.108
  24. Hebert JR, Corboy JR, Vollmer T, Forster JE, Schenkman M. Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS). Neurology. 2018 02 27; 90(9):e797-e807.
    View in: PubMed
    Score: 0.108
  25. Klein E, Solomon AJ, Corboy J, Bernat J. Physician compensation for industry-sponsored clinical trials in multiple sclerosis influences patient trust. Mult Scler Relat Disord. 2016 Jul; 8:4-8.
    View in: PubMed
    Score: 0.095
  26. Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016 Mar 15; 86(11):1014-21.
    View in: PubMed
    Score: 0.094
  27. Solomon AJ, Klein EP, Corboy JR, Bernat JL. Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics. Mult Scler. 2015 Oct; 21(12):1593-9.
    View in: PubMed
    Score: 0.088
  28. Waid DM, Schreiner T, Vaitaitis G, Carter JR, Corboy JR, Wagner DH. Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells. J Neuroimmunol. 2014 May 15; 270(1-2):75-85.
    View in: PubMed
    Score: 0.082
  29. Lafosse JM, Mitchell SM, Corboy JR, Filley CM. The nature of verbal memory impairment in multiple sclerosis: a list-learning and meta-analytic study. J Int Neuropsychol Soc. 2013 Oct; 19(9):995-1008.
    View in: PubMed
    Score: 0.080
  30. Hebert JR, Corboy JR, Manago MM, Schenkman M. Effects of vestibular rehabilitation on multiple sclerosis-related fatigue and upright postural control: a randomized controlled trial. Phys Ther. 2011 Aug; 91(8):1166-83.
    View in: PubMed
    Score: 0.068
  31. Nair KV, Corboy J, Kahler K, Allen RR, Ghushcyan V, McQueen RB, Bainbridge J, Dastani H, Mody-Patel N. Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis. Expert Rev Neurother. 2011 Jun; 11(6):787-98.
    View in: PubMed
    Score: 0.068
  32. Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, Schaeffer L, Kanter R, Brandes D, Kaufman C, Duncan D, Marder E, Allen A, Harney J, Cooper J, Woo D, St?ve O, Racke M, Frohman EM. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009 Apr; 256(4):568-76.
    View in: PubMed
    Score: 0.059
  33. Butler MA, Corboy JR, Filley CM. How the conflict between American psychiatry and neurology delayed the appreciation of cognitive dysfunction in multiple sclerosis. Neuropsychol Rev. 2009 Sep; 19(3):399-410.
    View in: PubMed
    Score: 0.059
  34. Amaria RN, Corboy JR, Finlayson CA, Robinson WA, Borges VF. Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review. Clin Breast Cancer. 2008 Oct; 8(5):449-52.
    View in: PubMed
    Score: 0.057
  35. Owens GP, Winges KM, Ritchie AM, Edwards S, Burgoon MP, Lehnhoff L, Nielsen K, Corboy J, Gilden DH, Bennett JL. VH4 gene segments dominate the intrathecal humoral immune response in multiple sclerosis. J Immunol. 2007 Nov 01; 179(9):6343-51.
    View in: PubMed
    Score: 0.053
  36. Lafosse JM, Corboy JR, Leehey MA, Seeberger LC, Filley CM. MS vs. HD: can white matter and subcortical gray matter pathology be distinguished neuropsychologically? J Clin Exp Neuropsychol. 2007 Feb; 29(2):142-54.
    View in: PubMed
    Score: 0.050
  37. Simon JH, Zhang S, Laidlaw DH, Miller DE, Brown M, Corboy J, Bennett J. Identification of fibers at risk for degeneration by diffusion tractography in patients at high risk for MS after a clinically isolated syndrome. J Magn Reson Imaging. 2006 Nov; 24(5):983-8.
    View in: PubMed
    Score: 0.049
  38. Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol. 2006 Apr; 63(4):614-9.
    View in: PubMed
    Score: 0.048
  39. Frohman EM, St?ve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol. 2005 Oct; 62(10):1519-30.
    View in: PubMed
    Score: 0.046
  40. Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BA, Hauser S, Racke MK. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol. 2005 Sep; 62(9):1345-56.
    View in: PubMed
    Score: 0.046
  41. Ritchie AM, Gilden DH, Williamson RA, Burgoon MP, Yu X, Helm K, Corboy JR, Owens GP. Comparative analysis of the CD19+ and CD138+ cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosis. J Immunol. 2004 Jul 01; 173(1):649-56.
    View in: PubMed
    Score: 0.042
  42. Frohman TC, Frohman EM, O'Suilleabhain P, Salter A, Dewey RB, Hogan N, Galetta S, Lee AG, Straumann D, Noseworthy J, Zee D, Corbett J, Corboy J, Rivera VM, Kramer PD. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. Neurology. 2003 Sep 23; 61(6):848-50.
    View in: PubMed
    Score: 0.040
  43. Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003 Sep 09; 61(5):602-11.
    View in: PubMed
    Score: 0.040
  44. Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol. 2003 Sep 01; 171(5):2725-33.
    View in: PubMed
    Score: 0.040
  45. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS, Storek J, Sullivan KM, Al-Omaishi J, Corboy JR, DiPersio J, Georges GE, Gooley TA, Holmberg LA, LeMaistre CF, Ryan K, Openshaw H, Sunderhaus J, Storb R, Zunt J, Kraft GH. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 2003 Oct 01; 102(7):2364-72.
    View in: PubMed
    Score: 0.039
  46. Williamson RA, Burgoon MP, Owens GP, Ghausi O, Leclerc E, Firme L, Carlson S, Corboy J, Parren PW, Sanna PP, Gilden DH, Burton DR. Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc Natl Acad Sci U S A. 2001 Feb 13; 98(4):1793-8.
    View in: PubMed
    Score: 0.033
  47. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012 Jul; 71(7):604-17.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)